ONC — BeOne Medicines AG Share Price
Last trade - 00:00- $30.50bn
- $29.07bn
- CNY27.21bn
- 77
- 21
- 99
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 73.32 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.69 | ||
| Price to Tang. Book | 9.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.86% | ||
| Return on Equity | -12.83% | ||
| Operating Margin | -7.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 2,120.2 | 7,588.96 | 9,566.41 | 17,423.34 | 27,213.96 | 36,785.31 | 44,405.93 | 55.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +310.65 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BeOne Medicines Ltd., formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Directors
- John Oyler CHM (53)
- Xiaobin Wu PRE (59)
- Xiaodong Wang CFD (57)
- Julia Wang CFO (50)
- Jane Huang OTH (48)
- Hing Ling Chau SEC
- Anthony Hooper NED (66)
- Timothy Chen NID (64)
- Han Dugan NID (65)
- Donald Glazer NID (76)
- Michael Goller NID (46)
- Ranjeev Krishana NID (47)
- Thomas Malley NID (52)
- Alessandro Riva NID (61)
- Corazon Sanders NID (64)
- Qingqing Yi NID (49)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- May 27th, 2025
- Public Since
- January 1st, 1970
- No. of Shareholders
- 31,718
- No. of Employees
- 11,075
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 1,539,857,262
- Address
- c/o BeOne Medicines I GmbH, BASEL, 4051
- Web
- Phone
- +41 616851900
- Auditors
- Ernst & Young LLP
Similar to ONC
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 16:16 UTC, shares in BeOne Medicines AG are trading at $257.51. This share price information is delayed by 15 minutes.
Shares in BeOne Medicines AG last closed at $257.51 and the price had moved by +64.95% over the past 365 days. In terms of relative price strength the BeOne Medicines AG share price has outperformed the S&P500 Index by +49.15% over the past year.
The overall consensus recommendation for BeOne Medicines AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBeOne Medicines AG does not currently pay a dividend.
BeOne Medicines AG does not currently pay a dividend.
BeOne Medicines AG does not currently pay a dividend.
To buy shares in BeOne Medicines AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $257.51, shares in BeOne Medicines AG had a market capitalisation of $30.50bn.
Here are the trading details for BeOne Medicines AG:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ONC
Based on an overall assessment of its quality, value and momentum BeOne Medicines AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BeOne Medicines AG is $323.32. That is 25.56% above the last closing price of $257.51.
Analysts covering BeOne Medicines AG currently have a consensus Earnings Per Share (EPS) forecast of CNY10.13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BeOne Medicines AG. Over the past six months, its share price has outperformed the S&P500 Index by +42.08%.
As of the last closing price of $257.51, shares in BeOne Medicines AG were trading +14.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BeOne Medicines AG PE ratio based on its reported earnings over the past 12 months is 73.32. The shares last closed at $257.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BeOne Medicines AG's management team is headed by:
- John Oyler - CHM
- Xiaobin Wu - PRE
- Xiaodong Wang - CFD
- Julia Wang - CFO
- Jane Huang - OTH
- Hing Ling Chau - SEC
- Anthony Hooper - NED
- Timothy Chen - NID
- Han Dugan - NID
- Donald Glazer - NID
- Michael Goller - NID
- Ranjeev Krishana - NID
- Thomas Malley - NID
- Alessandro Riva - NID
- Corazon Sanders - NID
- Qingqing Yi - NID